Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- BRC +12.2%
Other news:
- NXGN +10.9% (Thomas Bravo in advanced discussions to purchase NXGN, according to Bloomberg)
- DHC +10.6% (Diversified Healthcare Trust and Office Properties Income (OPI) trust mutually agree to terminate merger agreement)
- WVE +7% (announces the submission of its first clinical trial application for WVE-006 in alpha-1 antitrypsin deficiency)
- ABNB +5.6% (will join S&P 500)
- INSM +4.2% (topline results from Phase 3 ARISE study of arikayce (amikacin liposome inhalation suspension) in patients with ntm lung disease caused by MAC)
- BX +3.7% (will join S&P 500)
- XENE +3.6% (showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress)
- AUTL +3.3% (announces data from AUTO1/22 trial in pediatric Acute Lymphoblastic Leukemia published in the journal Blood)
- GNL +2.9% (to host conference call and Q&A to discuss benefits of merger and internalization transaction)
- RLYB +2.8% (presents Phase 1 single ascending dose data for RLYB116, an innovative subcutaneously injected inhibitor of complement component 5)
- OPAL +2.3% (announces new $500 million credit facility)
- HOLI +2.2% (notices of intention to request Special Meeting of Shareholders and additionally an unsolicited offer to acquire the company)
- VTRS +2% (receives FDA Tentative approval of a Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC))
- TRVG +1.7% (announcing a renewed focus on its brand marketing strategy; plans to issue a special one-time extraordinary dividend; no longer expects to exceed adjusted EBITDA of €70 million in 2023)
Analyst comments:
- AB +2.1% (upgraded to Buy from Neutral at BofA Securities)
- WWD +2% (upgraded to Outperform from Market Perform at TD Cowen)
- CNC +1.2% (upgraded to Neutral from Underperform at BofA Securities)
- SYK +1.1% (upgraded to Buy from Neutral at BofA Securities)